Transforming growth factor-β1 overexpression produces drug resistance in vivo: Reversal by decorin

In Vivo

Volumn 11, Issue 6, 1997, Pages 463-472

  Teicher, Beverly A ^a,b   Ikebe, Masahiko ^a   Ara, Gulshan ^a   Keyes, Susan R ^a   Herbst, Roy S ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Decorin; Drug resistance; Transforming growth factor 1

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ALKYLATING AGENT; CISPLATIN; DECORIN; MELPHALAN; THIOTEPA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; BONE MARROW; BREAST CARCINOMA; COLONY FORMING UNIT GM; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG SENSITIVITY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MONOLAYER CULTURE; NONHUMAN;

EID: 0031420122     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Teicher BA: In vivo resistance to antitumor alkylating agents, In: B. A. Teicher (eds.), Drug Resistance in Oncology, pp. 263-290. New York: Marcel Dekker, Inc., 1993.
2. Teicher BA: Preclinical models for high-dose therapy, In: JO Armitage and KH Antman (eds.), High-Dose Cancer Therapy, pp. 17-48. Philadelphia, PA: Williams & Wilkins, 1995.
3. Teicher BA, Herman TS, Holden SA, Wang Y, Pfeffer MR, Crawford JM and Frei III E: Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247: 1457-1461, 1990.
4. Teicher BA, Chatterjee D, Liu J-T, Holden SA and Ara G: Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors. Cancer Chemother. Pharmacol 32: 315-319, 1993.
5. Arteaga C, Dugger T, Winnier A and Forbes J: Evidence for a positive role of transforming growth factor-β in human breast cancer cell tumorgenesis. J Cellular Biochem 17G: 187-193, 1993.
6. Arteaga C, Carty-Dugger T, Moses H, Hurd S and Pietenpol J: Transforming growth factor β1 can induce estrogen-independent tumorgenicity of human breast cancer cells in athymic mice. Cell Growth Diff 4: 193-201, 1993.
7. Arteaga C, Hurd S, Winnier A, Johnson M, Fendly B and Forbes J: Antitransforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. J Clin Invest 92: 2569-2576, 1993.
8. Kaufmann A, Stoeck M, Schirrmacher V and Lichtner R: Transforming growth factor-beta production and induction of cellular responses in 13762NF rat mammary adenocarcinoma cell clones. Invasion Metastasis 13: 244-252, 1993.
9. Hsu S, Huang F, Hafez M, Winawer S and Friedman E: Colon carcinoma cells switch their response to transforming growth factor B1 with tumor prograssion. Cell Growth Diff 5: 267-275, 1994.
10. Lieubeau B, Garrigue L, Barbieux I, Meflah K and Gregoire M: The role of transforming growth factor β1 in the fibroblastic reaction associated with rat colorectal tumor development. Cancer Res 54: 6526-6532, 1994.
11. Maeda H, Tsuru S and Shiraishi A: Improvement of macrophage dysfunction by administration of anti-transforming growth factor-β antibody in EL4 bearing hosts. Jpn J Cancer Res 85: 1137-1143, 1994.
12. Elizalde P, Guerra F, Gravano M, Lanari C, Lippman M, Charreau E and Lupu R: Correlation of TGF-β1 expression with medroxiprogesterone acetate responsiveness in mouse mammary adenocarcinomas. Cancer Invest 13: 173-180, 1995.
13. Bailie R, Coombes R and Smith J: Multiple forms of TGF-β1 in breast tissues: bilogically active forms of the small latent complex of TGF-β1. Eur J Cancer 324: 1566-1573, 1996.
14. Steiner M and Barrack E: Transfroming growth factor-β1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinology 6: 15-25, 1992.
15. Steiner M, Zhou Z-Z, Tonb D and Barrack E: Expression of transforming growth factor-β1 in prostate cancer. Endocrinology 135: 2240-2247, 1994.
16. Anscher MS, Peters WP, Reisenbichler H, Petros WP and Jirtle RL: Transforming growth factor β as a predictor of liver and lung fibrosls after autologous bone marrow transplantation for advanced breast cancer. New Eng J Med 328: 1592-1598, 1993.
17. Arnoletti J, Albo D, Granick M, Castiglioni A, Rothman V and Tuszynski G: Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen-activator inhibitor-1 in human MDA-MB-231 breast cancer cells. Cancer 76: 998-1005, 1995.
18. MacCallum J, Bartlett JMS, Thompson AM, Keen JC, Dixon JM and Miller WR: Expression of transforming growth factor beta mRNA isoforms in human breast cancer. Br J Cancer 69: 1006-1009, 1994.
19. Wakefield L, Letterio J, Chen T, Danielpour D, Allison R, Pai L, Denicoff A, Noone M, Cowan K, O'Shaughnessy J and Sporn M: Transforming growth factor-β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 129-136, 1995.
20. Amoils K, Seyoum L and Bezwoda W: Comparison between immunocytochemical and polymerase chain reaction techniques for detection of oestrogen receptor and transforming growth factor β in breast cancer. Brit J Cancer 73: 1225-1259, 1996.
21. Walker RA, Dearing SJ and Gallacher B: Relationship of transforming growth factor β1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Br J Cancer 69: 1160-1165, 1994.
22. Murray P, Gomm J, Ricketts D, Powles T and Coombes R: The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-β1 in metastatic human breast cancer: an immunocytochemical study. Europ J Cancer 30A: 1218-1222, 1994.
23. MacCallum J, Keen J, Bartlett J, Thompson A, Dixon J and Miller W: Changes in expression of transforming growth factor beta mRNA isoforms in patients udergoing tamoxifen therapy. Brit J Cancer 74: 474-478, 1996.
24. Lafon C, Mazars P, Guerrin M, Barboule N, Charcosset J.-Y and Valette A: Early gene responses associated with transforming growth factor-β1- growth inhibition and autoinduction in MCF-7 breast adenocarcinoma cells. Biochim Biophys Acta 1266: 288-295, 1995.
25. Mazars P, Barboule N, Baldin V, Vidai S, Ducommun B and Valette A: Effects of TGF-β1 (transforming growth factor-β1) on the cell cycle regulation of human breast adenocarcinoma (MCF-7) cells. FEBS Lett 362: 295-300, 1995.
26. Herman ME and Katzenellenbogen BS: Alterations in transforming growth factor-α and -β production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res 54: 5867-5874, 1994.
27. Sun LZ, Wu G, Willson JKV Zborowska E, Yang J, Rajkarunanayake I, Wang J, Gentry LE, Wang X-F and Brattain MG: Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 269: 26449-26455, 1994.
28. Vrana J, Stang M, Gr ande J and Getz M: Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor β in breast cancer. Cancer Res 56: 5063-5070, 1996.
29. Derynck R, Jarrett J, Chen E, Eaton D, Bell J, Assoian R, Roberts A, Sporn M and Goeddel D: Human transforming growth factor-β cDNA sequence and expression in tumor cell lines. Nature 316: 701-705, 1985.
30. Arrick B, Lopez A, Elfman F, Ebner R, Damsky C and Derynck R: Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor-β1. J Cell Biol 118: 715-726, 1992.
31. Rheinwald JG: Serial cultivation of normal human epidermal keratinocytes. Methods of Cellular Biology 21: 229-254, 1980.
32. Teicher BA, Holden SA, Herman TS, Alvarez Sotomayor E, Khandekar V, Rosbe KW, Brann TW, Korbut TT and Frei III E: Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Int J Cancer 47: 252-260, 1991.
33. Teicher BA, Holden SA, Kelley MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD and Frei III E: Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res 47: 388-393, 1987.
34. Yamaguchi Y, Mann DM and Ruoslahti E: Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature 346: 281-284, 1990.
35. Chatterjee D, Liu JT, Northey D and Teicher BA: Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors. Cancer Chemother Pharmacol 35: 423-431, 1995.
36. Teicher B, Maehara Y, Kakeji Y, Ara G, Keyes S, Wong J and Herbst R: Reversal of in vivo drug resistance by the transforming growth factor-β inhibitor decorin. Int J Cancer, in press: 1997.
37. Teicher BA, Holden SA, Ara G and Chen G: Transforming growth factor-β in in vivo resistance. Cancer Chemother Pharmacol 37: 601-609, 1996.
38. Iozzo R and Cohen I: Altered proteoglcan gene expression and the tumor stroma. Experientia 49: 447-455, 1993.
39. Adany R, Heimer R, Caterson B, Sorrell J and Iozza R: Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. J Biol Chem 265; 11389-11396, 1990.
40. Mauviel A, Santra M, Chen Y, Uitto J and Iozzo R: Transcriptional regulation of decorin gene expression. J Biol Chem 270: 11692-11700, 1995.
41. Svensson L, Heinedard D and Oldberg A: Decorin-binding sites for collagen type I are mainly located in leucine-rich repeats 4-5. J Biol Chem 270: 20712-20716, 1995.
42. Santra M, Skorski T, Calabretta B, Lattime E and Iozzo R: De novo decorin gene expression suppressses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci USA 92: 7016-7020, 1995.
43. DeLuca A, Santra M, Baldi A, Giordano A and Iozzo R: Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclindependent kinases. J Biol Chem 271: 18961-18965, 1996.
44. Schonherr E, Hausser H, Beavan L and Kresse H: Decorin type I collagen interaction. J Biol Chem 270: 8877-8883, 1995.
45. Bittner K, Liszio C, Blumberg P, Schonherr E and Kresse H: Modulation of collagen gel contraction by decorin. Biochem J 314: 159-166, 1996.
46. Ramamurthy P, Hocking A and McQuillan D: Recombinant decorin glycoforms. J Biol Chem 271: 19578-19584, 1996.
47. Weber I, Harrison R and Iozzo R: Model structure of decorin and implications for collagen fibrillogenesis. J Biol Chem 271: 31767-31770, 1996.
48. Blaschke U, Hedbom E and Bruckner P: Distinct isoforms of chicken decorin contain either one or two dermatan sulfate chains. J Biol Chem 271: 30347-30353, 1996.
49. Roughly P, White R and Mort J: Presence of pro-forms of decorin and biglycan in human articular cartilage. Biochem J 318: 779-784, 1996.
50. Takeuchi Y, Kodama Y and Matsumoto T: Bone matrix decorin binds TGF-β and enhances its bioactivity. J Biol Chem 269: 32634-32638, 1994.
51. Border WA, Noble NA, Yamamoto K, Harper JR, Yamaguchi Y, Pierschbacher MD and Ruoslahti E: Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 360: 361-364, 1992.
52. Isaka Y, Brees D, Ikegaya K, Kaneda Y, Imai E, Noble N and Border W: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature 2: 418-423, 1996.
53. Anscher M, Kong F, Marks L, Bentel G and Jirtle R: Changes in plasma transfroming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Rad Oncol Biol Phys 37: 253-258, 1997.
54. Ayash L, Elias A and Schwartz G: Double dose intensive chemotherapy in autologous stem cell support for breast cancer: no improvement in progression free survival by the sequence of HD nel followed by CTX, Thio and Cb. J Clin Oncol in press: 1996.